The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study

Nick M. Spirtos, Danielle Enserro, Howard D. Homesley, Susan K. Gibbons, David Cella, Robert T. Morris, Koen DeGeest, Roger B. Lee, David S. Miller

Research output: Contribution to journalArticle

1 Scopus citations

Fingerprint Dive into the research topics of 'The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study'. Together they form a unique fingerprint.

Medicine & Life Sciences